Peyton Manning and Eli Manning are arguably the most famous sibling duo in NFL history. Both of them went on to have stellar careers in the league in their own right, with the star QBs each winning two Super

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in 2022 and 2023, respectively. Like Novo, it saw sales soar as doctors initially prescribed its diabetes drug off-label for weight loss too.

Conveniently, Peyton Manning and Ben Roethlisberger avoided playing Eli Manning in the Super Bwl, which he didn't let go unnoticed. Eli Manning is best known for beating Tom Brady in the Super Bowl (twice), but he never got to play his brother, Peyton Manning, or Pittsburgh Steelers legend Ben Roethlisberger in the big game.

Peyton Manning has cemented his legacy as one of the best NFL quarterbacks of all time, getting inducted into the Pro Football Hall of Fame in 2021 after winning two Super Bowls during an 18-season career. However, back in 1998, the future was more of a question mark.

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, practically became a household name. However, it has lost the top spot to its eternal rival, Eli Lilly ( LLY +1.64%).

Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

Eli Lilly working Humana to distribute obesity medications through employer-focused programs via CenterWell Pharmacy.

Despite Super Bowl rings and big plays, "Manning fatigue" may hurt his case. That would be a shame because Eli was a master of NFL moments.

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug approval expected Feb 2026.

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.